We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-6.73%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$517M
AUM Growth
-$90.9M
Cap. Flow
-$37.5M
Cap. Flow %
-7.26%
Top 10 Hldgs %
55.73%
Holding
40
New
7
Increased
5
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
TRVI icon
Trevi Therapeutics
TRVI
+$15.8M
2
TRML
Tourmaline Bio
TRML
+$14.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$12.8M
4
VSTM icon
Verastem
VSTM
+$10.5M
5
ATYR
aTyr Pharma
ATYR
+$9.67M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$25.2M
2
INSM icon
Insmed
INSM
+$22.9M
3
VRNA
Verona Pharma
VRNA
+$21.2M
4
DYN icon
Dyne Therapeutics
DYN
+$15.7M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 89.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
1
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$48.1M 9.31%
27,330,800
+27,018,464
+8,650% +$6.91M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$45.8M 8.86%
2,094,000
-912,980
-30% -$25.2M
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.68B
$42.5M 8.22%
2,341,667
+231,500
+11% +$5.1M
AVBP icon
4
ArriVent BioPharma
AVBP
$1.48B
$38.1M 7.37%
2,059,387
– –
TRVI icon
5
Trevi Therapeutics
TRVI
$2.49B
$20.9M 4.04%
+3,322,000
New +$15.8M
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
$20.5M 3.97%
1,425,000
-568,052
-29% -$9.3M
GOSS icon
7
Gossamer Bio
GOSS
$66.5M
$20.2M 3.91%
18,350,000
– –
OCUL icon
8
Ocular Therapeutix
OCUL
$1.86B
$17.8M 3.44%
2,425,000
– –
DFTX
9
Definium Therapeutics
DFTX
$5.73B
$17.7M 3.42%
3,018,000
– –
COGT icon
10
Cogent Biosciences
COGT
$6.79B
$16.6M 3.2%
2,763,000
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$15.8M 3.06%
1,370,000
– –
TSHA icon
12
Taysha Gene Therapies
TSHA
$1.59B
$14.9M 2.88%
10,700,000
+250,000
+2% +$418K
NUVB icon
13
Nuvation Bio
NUVB
$2.24B
$13.9M 2.69%
7,900,000
-1,302,907
-14% -$2.97M
VRNA
14
DELISTED
Verona Pharma
VRNA
$13.8M 2.67%
217,264
-354,000
-62% -$21.2M
TRML
15
DELISTED
Tourmaline Bio
TRML
$13.8M 2.66%
+905,000
New +$14.5M
MRUS
16
DELISTED
Merus
MRUS
$13M 2.51%
308,000
– –
PHVS icon
17
Pharvaris
PHVS
$2.39B
$12.1M 2.34%
769,815
-8,185
-1% -$138K
MLTX icon
18
MoonLake Immunotherapeutics
MLTX
$1.59B
$11.6M 2.24%
+296,000
New +$12.8M
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.84B
$11.1M 2.15%
904,000
– –
ATYR
20
aTyr Pharma
ATYR
$46.4M
$10.7M 2.08%
3,552,000
+2,652,000
+295% +$9.67M
SRRK icon
21
Scholar Rock
SRRK
$5.71B
$10.6M 2.05%
329,000
-159,000
-33% -$6.12M
VSTM icon
22
Verastem
VSTM
$532M
$10.4M 2.01%
+1,720,000
New +$10.5M
CNTA
23
PUT
DELISTED
Centessa Pharmaceuticals
CNTA
$8.63M 1.67%
600,000
+448,000
+295% +$7.33M
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$8.11M 1.57%
4,637,076
-211,726
-4% -$279K
SPRY icon
25
ARS Pharmaceuticals
SPRY
$590M
$7.86M 1.52%
+625,000
New +$7.52M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Octagon Capital Advisors held 40 positions worth $517M, down 15% from $608M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Octagon Capital Advisors withdrew a net $37.5M in Q1 2025, closing 5 positions and reducing 10 holdings. Its most notable exit was Insmed, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier.

Against the trend, Octagon Capital Advisors opened a new position in Trevi Therapeutics worth $20.9M.

  • Octagon Capital Advisors's largest Q1 2025 buy was Trevi Therapeutics: 3,322,000 shares worth $20.9M.
  • Octagon Capital Advisors added most to aTyr Pharma in Q1 2025, an estimated $9.67M increase.
  • Octagon Capital Advisors's biggest Q1 2025 reduction was Apellis Pharmaceuticals, cutting an estimated $25.2M.
  • Octagon Capital Advisors fully exited Insmed in Q1 2025, selling an estimated $22.9M.
  • Octagon Capital Advisors's ten largest holdings make up 56% of its $517M portfolio in Q1 2025.
  • Octagon Capital Advisors opened 7 new positions and closed 5 in Q1 2025.
  • Octagon Capital Advisors's portfolio value fell 15% quarter-over-quarter to $517M.

Based on Octagon Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.